M R Parkhurst

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
    M R Parkhurst
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:4895-901. 1998
  2. pmc T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:620-6. 2011
  3. pmc Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:169-80. 2009
  4. pmc Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase
    Maria R Parkhurst
    National Cancer Institute, Surgery Branch and National Heart, Lung, and Blood Institute, Hematology Branch, NIH, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 10:4688-98. 2004
  5. pmc Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:79-91. 2004
  6. pmc Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:5317-25. 2003
  7. pmc Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
    Maria R Parkhurst
    NIH, National Cancer Institute, Surgery Branch, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6287-97. 2011
  8. ncbi request reprint Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities
    John P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Room 2B42, Building 10, 9000 Rockville Pike, Bethesda, MD 20892 1502, USA
    J Immunol Methods 276:103-19. 2003
  9. pmc Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors
    Michal Lotem
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 29:616-27. 2006
  10. ncbi request reprint Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase
    J P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:212-20. 2001

Detail Information

Publications14

  1. ncbi request reprint Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
    M R Parkhurst
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:4895-901. 1998
    ..These results suggest that TRP2 may be useful for the development of murine tumor immunotherapy models and for the treatment of melanoma patients who are diverse in HLA expression...
  2. pmc T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:620-6. 2011
    ..It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy...
  3. pmc Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:169-80. 2009
    ..To develop an immunotherapy for patients with cancers that overexpress CEA, we isolated and genetically modified a T-cell receptors (TCRs) that specifically bound a CEA peptide on human cancer cells...
  4. pmc Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase
    Maria R Parkhurst
    National Cancer Institute, Surgery Branch and National Heart, Lung, and Blood Institute, Hematology Branch, NIH, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 10:4688-98. 2004
    ..Therefore, we initiated a clinical protocol to evaluate the therapeutic and immunological efficacy of this peptide...
  5. pmc Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:79-91. 2004
    ..These results suggest that recombinant tumor-associated proteins may be clinically applicable for the generation of CD4+ T helper cells in active vaccination strategies or adoptive cellular immunotherapies...
  6. pmc Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:5317-25. 2003
    ....
  7. pmc Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression
    Maria R Parkhurst
    NIH, National Cancer Institute, Surgery Branch, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6287-97. 2011
    ..Therefore, we initiated in a clinical trial to evaluate the efficacy of adoptively transferred autologous NK cells to treat patients with cancers who were ineligible for treatment with TIL...
  8. ncbi request reprint Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities
    John P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Room 2B42, Building 10, 9000 Rockville Pike, Bethesda, MD 20892 1502, USA
    J Immunol Methods 276:103-19. 2003
    ..These results suggest that the use of peptide mixtures may facilitate the identification of new tumor-associated antigens through the application of reverse immunology...
  9. pmc Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors
    Michal Lotem
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 29:616-27. 2006
    ..These data suggest that DCs transduced with viral vectors may be more efficient than DCs transfected with cDNAs or RNAs for the induction of tumor reactive CD8+ and CD4+ T cells in vitro and in human vaccination trials...
  10. ncbi request reprint Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase
    J P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:212-20. 2001
    ..1+ tyrosinase+ melanoma cells. These data suggest that tyrosinase:8-17 may be clinically useful for the treatment of patients with melanoma...
  11. ncbi request reprint MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte
    M I Nishimura
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 59:6230-8. 1999
    ....
  12. pmc Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy
    Steven A Rosenberg
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892, USA
    J Immunol 168:2402-7. 2002
    ..Overexpression was not found in normal tissues or other tumor types. Thus, BING-4 represents another candidate Ag for possible use in the immunotherapy of patients with melanoma...
  13. pmc Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells
    Steven A Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 22:107-15. 2011
    ..To date, this platform has generated five clinical-grade gammaretroviral vector products, four of which are now being used in adoptive cell therapy clinical trials for the treatment of a variety of solid cancers...
  14. pmc Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 67:2425-9. 2007
    ..The genetic manipulation of HSCs has broad implications for ACT of cancer...